SANOFI3,109.80

Sanofi India Limited

· Pharma & Health
₹ CrorePeersSENORESINNOVACAPPGHLMOREPENLABIOLCPSANOFICONRFDCORCHPHARMAMcap ₹7,153 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/12/2022
FY24
31/12/2023
FY25
31/12/2024
Revenue Growth+2.9-29.4
EBITDA Growth-3.7-38.9
EBIT Growth-3.6-40.6
Net Income Growth-31.4
EPS Growth-31.4
Total Assets Growth-17.2-6.0
Total Equity Growth-20.4-15.2
Cash from Operations Growth+100.3
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.